Aminopeptidase inhib 
Welcome,         Profile    Billing    Logout  
 4 Companies  3 Products   3 Products   34 Diseases   4 Trials   87 News 
4 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
tosedostat (CHR-2797) / SOBI
2011-000749-19: AML LI1

Ongoing
2/3
800
Europe
AC220 (Quizartinib), Ganetespib, Tosedostat, Selinexor, Revlimid, STA9090, CHR-2797, KPT-330, EMEA/H/C/000717 -PSUV/0074, Revlimid, Revlimid
Cardiff University
Acute myeloid leukemia and high-risk myelodysplastic syndrome
 
 
2009-014455-68: Study for patients with leukemic cells in their bone marrow.

Ongoing
2
240
Europe
tosedostat, CHR-2797, Capsule
HOVON Foundation, Haukeland University Hospital, Helse Bergen, HOVON Foundation, Chroma Therapeutics Ltd, Chrma Therapeutics Ltd, Haukeland University Hospital/HOVON
patients ≥ 66 years.with a confirmed diagnosis of o AML (not APL) (see appendix A) or o refractory anemia with excess of blasts (RAEB) with an IPSS score ≥ 1.5 OR Patients of any age ≥ 18 years with a confirmed diagnosis of o AML with very poor risk AML, Leukemia, cancer of bone marrow, Diseases [C] - Cancer [C04]
 
 
2011-001914-33: Study of CHR-3996 in combination with tosedostat in subjects with multiple myeloma

Ongoing
2
60
Europe
CHR-3996, Tosedostat, CHR-3996, CHR-2797,
University of Leeds
Relpsed or refractory multiple myeloma
 
 
PL37 / Debiopharm
2013-004876-37: A study to assess the effectiveness and safety of PL37 in reducing pain intensity when given in addition to gabapentin or pregabalin in patients suffering from neuropathic pain of diabetic origin, for whom ongoing treatment with gabapentin or pregabalin does not provide complete or sufficient relief of their neuropathic pain.

Ongoing
2
40
Europe
PL37, PL37,
Pharmaleads SA, Pharmaleads SA
Neuropathic pain develops as a result of damage to, or dysfunction of, the system that normally signals pain. It may arise from a heterogeneous group of disorders that affect the peripheral and central nervous systems. People with neuropathic pain may experience altered pain sensation, areas of numbness or burning, and continuous or intermittent evoked or spontaneous pain. In this study, neuropathic pain of diabetic origin is being investigated.
 
 
IC 805 / Pharmaleads, IACTA Pharma
No trials found
OPD5 / Oncopeptides
No trials found
IC800 / IACTA Pharma
No trials found
IC805 / IACTA Pharma
No trials found
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
tosedostat (CHR-2797) / SOBI
2011-000749-19: AML LI1

Ongoing
2/3
800
Europe
AC220 (Quizartinib), Ganetespib, Tosedostat, Selinexor, Revlimid, STA9090, CHR-2797, KPT-330, EMEA/H/C/000717 -PSUV/0074, Revlimid, Revlimid
Cardiff University
Acute myeloid leukemia and high-risk myelodysplastic syndrome
 
 
2009-014455-68: Study for patients with leukemic cells in their bone marrow.

Ongoing
2
240
Europe
tosedostat, CHR-2797, Capsule
HOVON Foundation, Haukeland University Hospital, Helse Bergen, HOVON Foundation, Chroma Therapeutics Ltd, Chrma Therapeutics Ltd, Haukeland University Hospital/HOVON
patients ≥ 66 years.with a confirmed diagnosis of o AML (not APL) (see appendix A) or o refractory anemia with excess of blasts (RAEB) with an IPSS score ≥ 1.5 OR Patients of any age ≥ 18 years with a confirmed diagnosis of o AML with very poor risk AML, Leukemia, cancer of bone marrow, Diseases [C] - Cancer [C04]
 
 
2011-001914-33: Study of CHR-3996 in combination with tosedostat in subjects with multiple myeloma

Ongoing
2
60
Europe
CHR-3996, Tosedostat, CHR-3996, CHR-2797,
University of Leeds
Relpsed or refractory multiple myeloma
 
 
PL37 / Debiopharm
2013-004876-37: A study to assess the effectiveness and safety of PL37 in reducing pain intensity when given in addition to gabapentin or pregabalin in patients suffering from neuropathic pain of diabetic origin, for whom ongoing treatment with gabapentin or pregabalin does not provide complete or sufficient relief of their neuropathic pain.

Ongoing
2
40
Europe
PL37, PL37,
Pharmaleads SA, Pharmaleads SA
Neuropathic pain develops as a result of damage to, or dysfunction of, the system that normally signals pain. It may arise from a heterogeneous group of disorders that affect the peripheral and central nervous systems. People with neuropathic pain may experience altered pain sensation, areas of numbness or burning, and continuous or intermittent evoked or spontaneous pain. In this study, neuropathic pain of diabetic origin is being investigated.
 
 
IC 805 / Pharmaleads, IACTA Pharma
No trials found
OPD5 / Oncopeptides
No trials found
IC800 / IACTA Pharma
No trials found
IC805 / IACTA Pharma
No trials found

Download Options